Literature DB >> 25262157

Antibodies to neurofascin exacerbate adoptive transfer experimental autoimmune neuritis.

Weixing Yan1, Toan Nguyen1, Nobuhiro Yuki2, Qiuhong Ji3, Con Yiannikas1, John D Pollard1, Emily K Mathey4.   

Abstract

Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy are autoimmune disorders of the peripheral nervous system in which autoantibodies are implicated in the disease pathogenesis. Recent work has focused on the nodal regions of the myelinated axon as potential autoantibody targets. Here we screened patient sera for autoantibodies to neurofascin and assessed the pathophysiological relevance of anti-neurofascin antibodies in vivo. Levels of anti-neurofascin antibodies were higher in sera from patients with Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy when compared with those of controls. Anti-neurofascin antibodies exacerbated and prolonged adoptive transfer experimental autoimmune neuritis and caused conduction defects when injected intraneurally.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Autoantibody; Chronic inflammatory demyelinating polyneuropathy; Guillain–Barré syndrome; Neurofascin; Nodes of Ranvier

Mesh:

Substances:

Year:  2014        PMID: 25262157     DOI: 10.1016/j.jneuroim.2014.09.012

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  22 in total

Review 1.  Autoantibodies in chronic inflammatory neuropathies: diagnostic and therapeutic implications.

Authors:  Luis Querol; Jérôme Devaux; Ricard Rojas-Garcia; Isabel Illa
Journal:  Nat Rev Neurol       Date:  2017-07-14       Impact factor: 42.937

Review 2.  Guillain-Barré syndrome: a century of progress.

Authors:  John A Goodfellow; Hugh J Willison
Journal:  Nat Rev Neurol       Date:  2016-11-18       Impact factor: 42.937

Review 3.  Regulatory T cell-based therapies for autoimmunity.

Authors:  Benjamine Arellano; David J Graber; Charles L Sentman
Journal:  Discov Med       Date:  2016-08       Impact factor: 2.970

Review 4.  Autoimmune antigenic targets at the node of Ranvier in demyelinating disorders.

Authors:  Panos Stathopoulos; Harry Alexopoulos; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-27       Impact factor: 42.937

5.  Anti-Neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo.

Authors:  Constance Manso; Luis Querol; Cinta Lleixà; Mallory Poncelet; Mourad Mekaouche; Jean-Michel Vallat; Isabel Illa; Jérôme J Devaux
Journal:  J Clin Invest       Date:  2019-03-14       Impact factor: 14.808

Review 6.  Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features.

Authors:  Lisha Tang; Qianyi Huang; Zhen Qin; Xiangqi Tang
Journal:  J Neurol       Date:  2020-04-07       Impact factor: 4.849

Review 7.  Neurofascin antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: from intrinsic genetic background to clinical manifestations.

Authors:  Ze Wang; Xiajun Zhou; Nan Zhao; Chong Xie; Desheng Zhu; Yangtai Guan
Journal:  Neurol Sci       Date:  2021-03-29       Impact factor: 3.307

Review 8.  The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Kathleen M Hagen; Shalina S Ousman
Journal:  J Neuroinflammation       Date:  2021-03-22       Impact factor: 8.322

Review 9.  Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism.

Authors:  Jun-Ichi Kira
Journal:  Front Neurol       Date:  2021-06-10       Impact factor: 4.003

Review 10.  Biomarkers of Guillain-Barré Syndrome: Some Recent Progress, More Still to Be Explored.

Authors:  Ying Wang; Shuang Sun; Jie Zhu; Li Cui; Hong-Liang Zhang
Journal:  Mediators Inflamm       Date:  2015-09-16       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.